Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes

Valeria Judkowski, Enrique Rodriguez, Clemencia Pinilla, Emma Masteller, Jeffrey A. Bluestone, Nora E Sarvetnick, Darcy B. Wilson

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

NOD mice spontaneously develop insulitis and type 1 diabetes (T1D) mellitus similar to humans. Insulitis without overt disease occurs in the BDC2.5 TCR-transgenic NOD mice that express the rearranged TCR α- and β-chain genes of a diabetogenic T cell clone reactive to an unknown β cell autoantigen. A previous study identified an extensive panel of peptides that are highly active in stimulating T cells from transgenic BDC2.5 mice in culture. However, none of these peptides cause active disease in NOD and BDC2.5 animals or in NOD recipients of adoptively transferred BDC2.5 T cells following direct immunization in vivo. We show that direct immunization of transgenic BDC2.5 mice causes many BDC2.5 T cells to become activated and apoptotic. Strikingly, soluble peptides administered to recipients of activated, highly pathogenic BDC2.5 T cells results in protection from disease. These results suggest that high affinity peptide analogues of autoimmune epitopes might be useful as therapeutic modulators in active autoimmune disease.

Original languageEnglish (US)
Pages (from-to)29-37
Number of pages9
JournalClinical Immunology
Volume113
Issue number1
DOIs
StatePublished - Oct 1 2004
Externally publishedYes

Fingerprint

Type 1 Diabetes Mellitus
T-Lymphocytes
Peptides
Transgenic Mice
Inbred NOD Mouse
Immunization
Autoantigens
Autoimmune Diseases
Epitopes
Clone Cells
Genes
Therapeutics

Keywords

  • Autoimmunity
  • BDC2.5 mice
  • Diabetes
  • EC
  • IDDM
  • NOD
  • NOD mice
  • Peptide antigens
  • SI
  • T cell receptor
  • T1D
  • TCR
  • insulin-dependent diabetes mellitus
  • nonobese diabetic
  • the concentration of peptide that stimulates a half-maximal response
  • type 1 diabetes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Judkowski, V., Rodriguez, E., Pinilla, C., Masteller, E., Bluestone, J. A., Sarvetnick, N. E., & Wilson, D. B. (2004). Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes. Clinical Immunology, 113(1), 29-37. https://doi.org/10.1016/j.clim.2004.03.007

Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes. / Judkowski, Valeria; Rodriguez, Enrique; Pinilla, Clemencia; Masteller, Emma; Bluestone, Jeffrey A.; Sarvetnick, Nora E; Wilson, Darcy B.

In: Clinical Immunology, Vol. 113, No. 1, 01.10.2004, p. 29-37.

Research output: Contribution to journalArticle

Judkowski, V, Rodriguez, E, Pinilla, C, Masteller, E, Bluestone, JA, Sarvetnick, NE & Wilson, DB 2004, 'Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes', Clinical Immunology, vol. 113, no. 1, pp. 29-37. https://doi.org/10.1016/j.clim.2004.03.007
Judkowski, Valeria ; Rodriguez, Enrique ; Pinilla, Clemencia ; Masteller, Emma ; Bluestone, Jeffrey A. ; Sarvetnick, Nora E ; Wilson, Darcy B. / Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes. In: Clinical Immunology. 2004 ; Vol. 113, No. 1. pp. 29-37.
@article{84bf0d322f8841ddbd424dfe0bcf7192,
title = "Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes",
abstract = "NOD mice spontaneously develop insulitis and type 1 diabetes (T1D) mellitus similar to humans. Insulitis without overt disease occurs in the BDC2.5 TCR-transgenic NOD mice that express the rearranged TCR α- and β-chain genes of a diabetogenic T cell clone reactive to an unknown β cell autoantigen. A previous study identified an extensive panel of peptides that are highly active in stimulating T cells from transgenic BDC2.5 mice in culture. However, none of these peptides cause active disease in NOD and BDC2.5 animals or in NOD recipients of adoptively transferred BDC2.5 T cells following direct immunization in vivo. We show that direct immunization of transgenic BDC2.5 mice causes many BDC2.5 T cells to become activated and apoptotic. Strikingly, soluble peptides administered to recipients of activated, highly pathogenic BDC2.5 T cells results in protection from disease. These results suggest that high affinity peptide analogues of autoimmune epitopes might be useful as therapeutic modulators in active autoimmune disease.",
keywords = "Autoimmunity, BDC2.5 mice, Diabetes, EC, IDDM, NOD, NOD mice, Peptide antigens, SI, T cell receptor, T1D, TCR, insulin-dependent diabetes mellitus, nonobese diabetic, the concentration of peptide that stimulates a half-maximal response, type 1 diabetes",
author = "Valeria Judkowski and Enrique Rodriguez and Clemencia Pinilla and Emma Masteller and Bluestone, {Jeffrey A.} and Sarvetnick, {Nora E} and Wilson, {Darcy B.}",
year = "2004",
month = "10",
day = "1",
doi = "10.1016/j.clim.2004.03.007",
language = "English (US)",
volume = "113",
pages = "29--37",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes

AU - Judkowski, Valeria

AU - Rodriguez, Enrique

AU - Pinilla, Clemencia

AU - Masteller, Emma

AU - Bluestone, Jeffrey A.

AU - Sarvetnick, Nora E

AU - Wilson, Darcy B.

PY - 2004/10/1

Y1 - 2004/10/1

N2 - NOD mice spontaneously develop insulitis and type 1 diabetes (T1D) mellitus similar to humans. Insulitis without overt disease occurs in the BDC2.5 TCR-transgenic NOD mice that express the rearranged TCR α- and β-chain genes of a diabetogenic T cell clone reactive to an unknown β cell autoantigen. A previous study identified an extensive panel of peptides that are highly active in stimulating T cells from transgenic BDC2.5 mice in culture. However, none of these peptides cause active disease in NOD and BDC2.5 animals or in NOD recipients of adoptively transferred BDC2.5 T cells following direct immunization in vivo. We show that direct immunization of transgenic BDC2.5 mice causes many BDC2.5 T cells to become activated and apoptotic. Strikingly, soluble peptides administered to recipients of activated, highly pathogenic BDC2.5 T cells results in protection from disease. These results suggest that high affinity peptide analogues of autoimmune epitopes might be useful as therapeutic modulators in active autoimmune disease.

AB - NOD mice spontaneously develop insulitis and type 1 diabetes (T1D) mellitus similar to humans. Insulitis without overt disease occurs in the BDC2.5 TCR-transgenic NOD mice that express the rearranged TCR α- and β-chain genes of a diabetogenic T cell clone reactive to an unknown β cell autoantigen. A previous study identified an extensive panel of peptides that are highly active in stimulating T cells from transgenic BDC2.5 mice in culture. However, none of these peptides cause active disease in NOD and BDC2.5 animals or in NOD recipients of adoptively transferred BDC2.5 T cells following direct immunization in vivo. We show that direct immunization of transgenic BDC2.5 mice causes many BDC2.5 T cells to become activated and apoptotic. Strikingly, soluble peptides administered to recipients of activated, highly pathogenic BDC2.5 T cells results in protection from disease. These results suggest that high affinity peptide analogues of autoimmune epitopes might be useful as therapeutic modulators in active autoimmune disease.

KW - Autoimmunity

KW - BDC2.5 mice

KW - Diabetes

KW - EC

KW - IDDM

KW - NOD

KW - NOD mice

KW - Peptide antigens

KW - SI

KW - T cell receptor

KW - T1D

KW - TCR

KW - insulin-dependent diabetes mellitus

KW - nonobese diabetic

KW - the concentration of peptide that stimulates a half-maximal response

KW - type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=6044257565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6044257565&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2004.03.007

DO - 10.1016/j.clim.2004.03.007

M3 - Article

VL - 113

SP - 29

EP - 37

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 1

ER -